ZURICH (dpa-AFX) - Shares in dialysis group FMC came under pressure on Monday after a sell recommendation by major Swiss bank UBS. They fell 1.41 percent to 46.90 in late morning trading, dropping below the 21-day line, which is now down. This average price is considered an indicator of the short-term trend.

UBS analyst Graham Doyle believes the market's earnings expectations for the Fresenius subsidiary are too high. In addition, there are major uncertainties regarding future business prospects. For example, new diabetes therapies developed in recent years could soon have a negative impact on the number of dialysis patients.

In addition, there were recent study data on the weight-loss drug semaglutide, which is used for diabetics. The data had shown a reduction in cardiovascular risk, which is why the assessment that the drug could protect the kidneys was also accepted, explains Doyle.

Against this background, the analyst lowered FMC's price target from 43.50 euros to 42.00 euros and downgraded the papers from "Neutral" to "Sell."

Shares in FMC's parent company Fresenius held on to a narrow gain of 0.13 percent on Monday, but trailed the Dax./mis/nas/jha/